Influenza – Pipeline Review, H1 2012
Reference Code: GMDHC1734IDB
Publication Date: February 2012
Influenza – Pipeline Review, H1 2012 GMDHC1734IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)
Influenza – Pipeline Review, H1 2012
Table of Contents
Table of Contents ............................................................................................................................................................................... 2
List of Tables ................................................................................................................................................................................. 9
List of Figures .............................................................................................................................................................................. 12
Introduction....................................................................................................................................................................................... 13
Global Markets Direct Report Coverage ...................................................................................................................................... 13
Influenza Overview ........................................................................................................................................................................... 14
Therapeutics Development............................................................................................................................................................... 15
An Overview of Pipeline Products for Influenza ........................................................................................................................... 15
Influenza Therapeutics under Development by Companies ............................................................................................................. 17
Influenza Therapeutics under Investigation by Universities/Institutes .............................................................................................. 26
Late Stage Products ......................................................................................................................................................................... 30
Comparative Analysis .................................................................................................................................................................. 30
Mid Clinical Stage Products.............................................................................................................................................................. 31
Comparative Analysis .................................................................................................................................................................. 31
Early Clinical Stage Products ........................................................................................................................................................... 32
Comparative Analysis .................................................................................................................................................................. 32
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 33
Comparative Analysis .................................................................................................................................................................. 33
Influenza Therapeutics – Products under Development by Companies ........................................................................................... 34
Influenza Therapeutics – Products under Investigation by Universities/Institutes ............................................................................ 48
Companies Involved in Influenza Therapeutics Development .......................................................................................................... 54
Baxter International Inc................................................................................................................................................................ 54
Johnson & Johnson ..................................................................................................................................................................... 55
Vical Incorporated........................................................................................................................................................................ 56
Sanofi-Aventis ............................................................................................................................................................................. 57
AstraZeneca PLC ........................................................................................................................................................................ 58
GlaxoSmithKline plc .................................................................................................................................................................... 59
Inovio Biomedical Corporation ..................................................................................................................................................... 60
MedImmune LLC ......................................................................................................................................................................... 61
Daiichi Sankyo Company, Ltd...................................................................................................................................................... 62
Emergent BioSolutions Inc. ......................................................................................................................................................... 63
Lentigen Corporation ................................................................................................................................................................... 64
Generex Biotechnology Corporation............................................................................................................................................ 65
Celltrion, Inc................................................................................................................................................................................. 66
Nanotherapeutics, Inc.................................................................................................................................................................. 67
Liquidia Technologies, Inc. .......................................................................................................................................................... 68
Novartis AG ................................................................................................................................................................................. 69
Aphios Corporation ...................................................................................................................................................................... 70
Mitsubishi Chemical Holdings Corporation .................................................................................................................................. 71
Novavax, Inc. ............................................................................................................................................................................... 72
Toyama Chemical Co. Ltd ........................................................................................................................................................... 73
CEL-SCI Corporation................................................................................................................................................................... 74
Influenza – Pipeline Review, H1 2012 GMDHC1734IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2)
Influenza – Pipeline Review, H1 2012
AVI BioPharma Inc. ..................................................................................................................................................................... 75
Crucell N.V. ................................................................................................................................................................................. 76
OPKO Health, Inc. ....................................................................................................................................................................... 77
Zosano Pharma, Inc. ................................................................................................................................................................... 78
Hemispherx Biopharma, Inc. ....................................................................................................................................................... 79
Intercell AG .................................................................................................................................................................................. 80
Medicago Inc. .............................................................................................................................................................................. 81
BioDiem Ltd ................................................................................................................................................................................. 82
Biota Holdings Limited ................................................................................................................................................................. 83
Mymetics Corporation.................................................................................................................................................................. 84
NanoViricides, Inc........................................................................................................................................................................ 85
NovaBay Pharmaceuticals, Inc. ................................................................................................................................................... 86
Oramed Pharmaceuticals, Inc. .................................................................................................................................................... 87
CytoGenix, Inc. ............................................................................................................................................................................ 88
Amarillo Biosciences, Inc............................................................................................................................................................. 89
BioCryst Pharmaceuticals, Inc. .................................................................................................................................................... 90
Dynavax Technologies Corporation............................................................................................................................................. 91
Immuron Limited .......................................................................................................................................................................... 92
Lipoxen PLC ................................................................................................................................................................................ 93
Green Cross Corporation ............................................................................................................................................................ 94
Cytos Biotechnology AG .............................................................................................................................................................. 95
SCOLR Pharma, Inc. ................................................................................................................................................................... 96
Synairgen plc ............................................................................................................................................................................... 97
Eurocine Vaccines AB ................................................................................................................................................................. 98
Antigen Express, Inc.................................................................................................................................................................... 99
Avanti Therapeutics ................................................................................................................................................................... 100
Marinomed Biotechnologie GmbH ............................................................................................................................................. 101
Nutri Pharma ASA ..................................................................................................................................................................... 102
LigoCyte Pharmaceuticals, Inc. ................................................................................................................................................. 103
Evolva SA .................................................................................................................................................................................. 104
Vironova AB............................................................................................................................................................................... 105
CureVac GmbH ......................................................................................................................................................................... 106
TechnoVax, Inc.......................................................................................................................................................................... 107
MacroGenics, Inc....................................................................................................................................................................... 108
Pulmatrix, Inc. ............................................................................................................................................................................ 109
Okairos ...................................................................................................................................................................................... 110
Viroblock S.A. ............................................................................................................................................................................ 111
AlphaVax, Inc. ........................................................................................................................................................................... 112
Innate Therapeutics Limited ...................................................................................................................................................... 113
Vaxin, Inc. .................................................................................................................................................................................. 114
Indus Biotech Private Limited .................................................................................................................................................... 115
Romark Laboratories, L.C. ........................................................................................................................................................ 116
Adamas Pharmaceuticals, Inc. .................................................................................................................................................. 117
Theraclone Sciences, Inc. ......................................................................................................................................................... 118
Influenza – Pipeline Review, H1 2012 GMDHC1734IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(3)
Influenza – Pipeline Review, H1 2012
REPLICor Inc............................................................................................................................................................................. 119
Immune Targeting Systems (ITS) Ltd. ....................................................................................................................................... 120
Sinovac Biotech Ltd. .................................................................................................................................................................. 121
Atox Bio Inc. .............................................................................................................................................................................. 122
Juvaris BioTherapeutics, Inc...................................................................................................................................................... 123
NanoBio Corporation ................................................................................................................................................................. 124
Protein Sciences Corporation .................................................................................................................................................... 125
ImmunoVaccine Technologies Inc. ............................................................................................................................................ 126
VaxInnate Corporation............................................................................................................................................................... 127
Globeimmune, Inc. .................................................................................................................................................................... 128
Etubics Corporation ................................................................................................................................................................... 129
Obio Pharmaceutical Holdings Limited. ..................................................................................................................................... 130
Canopus BioPharma Incorporated ............................................................................................................................................ 131
iBio, Inc...................................................................................................................................................................................... 132
PepTcell Limited ........................................................................................................................................................................ 133
BiondVax Pharmaceuticals Ltd. ................................................................................................................................................. 134
Avir Green Hills Biotechnology AG ............................................................................................................................................ 135
Sirnaomics, Inc. ......................................................................................................................................................................... 136
Vaxart, Inc. .......................................................